Delving into the Latest Updates on Guangzhou Lansheng Jianzhi Pharmaceutical Technology with Synapse

Overview

Tags

Nervous System Diseases

Endocrinology and Metabolic Disease

Cardiovascular Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	3
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	3

Top 5 Target	Count

PDE4(Phosphodieterase 4)	1
PI3Kγ x PI3Kδ	1
M4 receptor(Muscarinic acetylcholine receptor M4)	1

Primary purpose: To evaluate the safety and tolerability of LS001 in patients with early and middle stage Parkinson's disease. Secondary purpose: To evaluate the pharmacokinetic characteristics and efficacy of LS001 in patients with early and middle stage Parkinson's disease; to explore the metabolites of L-demethylphencyclonate hydrochloride in patients with Parkinson's disease.

Start Date01 Mar 2022

Sponsor / Collaborator

Academy of Military Med Sci, Inst of Toxicology & Pharmacology

[+1]

CTR20212522

/ RecruitingPhase 2

左旋盐酸去甲基苯环壬酯片（LS001）治疗早、中期帕金森病的随机、双盲、安慰剂对照的剂量探索和耐受性研究

[Translation] A randomized, double-blind, placebo-controlled, dose-finding and tolerability study of LS001 in the treatment of early and mid-stage Parkinson's disease

主要目的：评价LS001在早、中期帕金森病患者中的安全性和耐受性次要目的：评价LS001治疗早、中期帕金森病的初步有效性以及在早、中期帕金森病群体药代动力学特征

[Translation]

Primary objective: To evaluate the safety and tolerability of LS001 in patients with early and middle stage Parkinson's disease Secondary objective: To evaluate the preliminary efficacy of LS001 in the treatment of early and middle stage Parkinson's disease and its pharmacokinetic characteristics in the early and middle stage Parkinson's disease population

Start Date24 Dec 2021

Sponsor / Collaborator

Academy of Military Med Sci, Inst of Toxicology & Pharmacology

[+1]

CTR20212501

/ CompletedPhase 1

左旋盐酸去甲基苯环壬酯片在健康受试者中的食物影响研究

[Translation] Study on the food effect of L-demethylphencyclonate hydrochloride tablets in healthy subjects

主要目的：观察在中国健康成年受试者中食物对LS001药代动力学特征的影响。次要目的：评价LS001在健康受试者中空腹/餐后服用的安全性；评价LS001在健康受试者中空腹给药后代谢产物的药代动力学特征。

[Translation]

Primary objective: To observe the effect of food on the pharmacokinetic characteristics of LS001 in healthy adult subjects in China. Secondary objective: To evaluate the safety of LS001 in healthy subjects after fasting/postprandial administration; To evaluate the pharmacokinetic characteristics of metabolites of LS001 after fasting administration in healthy subjects.

Start Date19 Oct 2021

Sponsor / Collaborator

Academy of Military Med Sci, Inst of Toxicology & Pharmacology

[+1]

100 Clinical Results associated with Guangzhou Lansheng Jianzhi Pharmaceutical Technology

Login to view more data

0 Patents (Medical) associated with Guangzhou Lansheng Jianzhi Pharmaceutical Technology

Login to view more data

100 Deals associated with Guangzhou Lansheng Jianzhi Pharmaceutical Technology

Login to view more data

100 Translational Medicine associated with Guangzhou Lansheng Jianzhi Pharmaceutical Technology

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 09 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

1

IND Approval

Phase 2 Clinical

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

L-Demethyl Phencynonate Hydrochloride ( M4 receptor )	Parkinson Disease More	Phase 2
LS21031 ( PDE4 )	Depressive Disorder More	IND Approval
ZX-101 ( PI3Kγ x PI3Kδ )	Alzheimer Disease More	Preclinical
FCPR-16 ( PDE4 )	Ischemic stroke More	Preclinical